{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T21:51:26Z","timestamp":1776203486552,"version":"3.50.1"},"reference-count":157,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.beem.2009.05.003","type":"journal-article","created":{"date-parts":[[2009,11,27]],"date-time":"2009-11-27T22:02:29Z","timestamp":1259359349000},"page":"575-596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":128,"title":["The prolactinoma"],"prefix":"10.1016","volume":"23","author":[{"given":"Annamaria","family":"Colao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2009.05.003_bib1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam","year":"2006","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.beem.2009.05.003_bib2","first-page":"2035","volume":"349","author":"Schlechte","year":"2003","journal-title":"Clinical practice. Prolactinoma. The New England Journal of Medicine"},{"key":"10.1016\/j.beem.2009.05.003_bib3","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/S0140-6736(98)03356-X","article-title":"Growth hormone and prolactin excess","volume":"352","author":"Colao","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2009.05.003_bib4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2265.1991.tb00299.x","article-title":"Management of prolactinomas","volume":"34","author":"Cunnah","year":"1991","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib5","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1210\/jc.2006-1668","article-title":"High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium","volume":"91","author":"Daly","year":"2006","journal-title":"The Journal of Clinical Endocrinology Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/eje.0.1480325","article-title":"Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia","volume":"148","author":"Colao","year":"2003","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2265.1994.tb02557.x","article-title":"Age-related and gender-related occurrence of pituitary adenomas","volume":"41","author":"Mindermann","year":"1994","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib8","unstructured":"Colao A. Pituitary tumors in childhood. In: New MI [ed] Endotext.org, 2004."},{"key":"10.1016\/j.beem.2009.05.003_bib9","first-page":"1841","article-title":"Prolactinomas in a large kindred with multiple endocrine neoplasia type 1: clinical features and inheritance pattern","volume":"81","author":"Burgess","year":"1996","journal-title":"The Journal of Clinical Endocrinology Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1210\/jcem.87.2.8145","article-title":"Pituitary disease in MEN type 1 [MEN1]: data from the France-Belgium MEN1 multicenter study","volume":"87","author":"Verg\u00e8s","year":"2002","journal-title":"The Journal of Clinical Endocrinology Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib11","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1056\/NEJM198101153040306","article-title":"Microadenomas of the pituitary gland and abnormal sellar tomograms in an unselected autopsy series","volume":"304","author":"Burrow","year":"1980","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beem.2009.05.003_bib12","first-page":"2102","article-title":"Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study","volume":"82","author":"Delgrange","year":"1997","journal-title":"The Journal of Clinical Endocrinology Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib13","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/BF03349742","article-title":"Prolactinoma in 53 men: clinical characteristics and modes of treatment (male prolactinoma)","volume":"18","author":"Berezin","year":"1995","journal-title":"Journal of Endocrinological Investigation"},{"key":"10.1016\/j.beem.2009.05.003_bib14","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1445-5994.1997.tb02196.x","article-title":"Hyperprolactinaemia in males: a heterogeneous disorder","volume":"27","author":"Walsh","year":"1997","journal-title":"Australian and New Zealand Journal of Medicine"},{"key":"10.1016\/j.beem.2009.05.003_bib15","first-page":"3053","article-title":"Primary medical therapy of micro- and macroprolactinomas in men","volume":"85","author":"Pinzone","year":"2000","journal-title":"The Journal of Clinical Endocrinology Metabolism"},{"issue":"1\u20132","key":"10.1016\/j.beem.2009.05.003_bib16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1385\/ENDO:20:1-2:75","article-title":"Hyperprolactinemia in men. Clinical and biochemical features and response to treatment","volume":"20","author":"De Rosa","year":"2003","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2009.05.003_bib17","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/sj.ijir.3900675","article-title":"Severe erectile dysfunction is a marker for hyperprolactinemia","volume":"13","author":"Johri","year":"2001","journal-title":"International Journal of Impotence Research"},{"key":"10.1016\/j.beem.2009.05.003_bib18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/sj.ijir.3900473","article-title":"Experimental hyperprolactinemia in a rat model: alteration in centrally mediated neuroerectile mechanism","volume":"12","author":"Rehman","year":"2000","journal-title":"International Journal of Impotence Research"},{"issue":"2","key":"10.1016\/j.beem.2009.05.003_bib19","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1210\/jc.2003-030852","article-title":"Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence","volume":"89","author":"De Rosa","year":"2004","journal-title":"The Journal of Clinical Endocrinology Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib20","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/j.1365-2265.2007.02973.x","article-title":"Body fat in nonobese women with prolactinoma treated with dopamine agonists","volume":"67","author":"Naliato","year":"2007","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib21","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-110-7-526","article-title":"Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism","volume":"110","author":"Greenspan","year":"1989","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.beem.2009.05.003_bib22","first-page":"933","article-title":"Prevalence and magnitude of osteopenia in patients with prolactinoma","volume":"26","author":"Kayath","year":"1993","journal-title":"Brazilian Journal of Medical and Biological Research"},{"key":"10.1016\/j.beem.2009.05.003_bib23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1046\/j.1365-2265.2000.00902.x","article-title":"Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization","volume":"52","author":"Colao","year":"2000","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1530\/EJE-07-0259","article-title":"Quality of life is decreased in female patients treated for microprolactinoma","volume":"157","author":"Kars","year":"2007","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib25","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11102-008-0091-9","article-title":"Quality of life in women with microprolactinoma treated with dopamine agonists","volume":"11","author":"Cesar de Oliveira Naliato","year":"2008","journal-title":"Pituitary"},{"issue":"7 Suppl.","key":"10.1016\/j.beem.2009.05.003_bib26","first-page":"39","article-title":"An evaluation of patients with hyperprolactinemia: have dynamic tests had their day?","volume":"26","author":"Di Sarno","year":"2003","journal-title":"Journal of Endocrinological Investigation"},{"key":"10.1016\/j.beem.2009.05.003_bib27","first-page":"3507","article-title":"Some forms of big big prolactin behave as a complex of monomeric with an immunoglobulin G in patients with macroprolactinoma or prolactinomas","volume":"80","author":"Cavaco","year":"1995","journal-title":"The Journal of Clinical Endocrinology Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib28","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1530\/eje.0.1300434","article-title":"Effects of antiprolactin autoantibodies on serum prolactin measurements","volume":"130","author":"Hattori","year":"1994","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib29","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/BF03347299","article-title":"Pituitary adenomas secreting large amounts of prolactin may give\u00a0false low values in immunoradiometric assays. The hook effect","volume":"21","author":"Petakov","year":"1998","journal-title":"Journal of Endocrinological Investigation"},{"issue":"12 Suppl.","key":"10.1016\/j.beem.2009.05.003_bib30","first-page":"1095","article-title":"Diagnostic evaluation of hyperprolactinemia","volume":"44","author":"Biller","year":"1999","journal-title":"The Journal of Reproductive Medicine"},{"key":"10.1016\/j.beem.2009.05.003_bib31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.7326\/0003-4819-100-1-115","article-title":"Hyperprolactinemia, amenorrhea, and galactorrhea. A retrospective assessment of twenty-five cases","volume":"100","author":"Koppelman","year":"1984","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.beem.2009.05.003_bib32","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0002-9378(81)90553-6","article-title":"Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas","volume":"139","author":"March","year":"1981","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1016\/j.beem.2009.05.003_bib33","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1210\/jcem-68-2-412","article-title":"The natural history of untreated hyperprolactinemia: a prospective analysis","volume":"68","author":"Schlechte","year":"1989","journal-title":"The\u00a0Journal of Clinical Endocrinology Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0015-0282(16)59292-9","article-title":"The natural history of untreated microprolactinomas","volume":"48","author":"Sisam","year":"1987","journal-title":"Fertility and Sterility"},{"key":"10.1016\/j.beem.2009.05.003_bib35","first-page":"175","article-title":"Development of hyperprolactinemia in patients with adenomas with and without prior operative treatment","volume":"584","author":"Von Werder","year":"1982","journal-title":"Excerpta Medica International Congress series"},{"key":"10.1016\/j.beem.2009.05.003_bib36","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1227\/00006123-198302000-00008","article-title":"Natural history of microprolactinomas: six-year follow-up","volume":"12","author":"Weiss","year":"1983","journal-title":"Neurosurgery"},{"key":"10.1016\/j.beem.2009.05.003_bib37","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1055\/s-0029-1211978","article-title":"Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study","volume":"106","author":"Hofle","year":"1998","journal-title":"Experimental and Clinical Endocrinology & Diabetes"},{"key":"10.1016\/j.beem.2009.05.003_bib38","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/ncpendmet0968","article-title":"Pituitary apoplexy within a macroprolactinoma","volume":"4","author":"Watt","year":"2008","journal-title":"Nature Clinical Practice Endocrinology & Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1023\/A:1009991631761","article-title":"Endoscopic pituitary surgery","volume":"2","author":"Jho","year":"1999","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2009.05.003_bib40","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1227\/01.NEU.0000137330.02549.0D","article-title":"Endoscopic endonasal transsphenoidal surgery","volume":"55","author":"Cappabianca","year":"2004","journal-title":"Neurosurgery"},{"key":"10.1016\/j.beem.2009.05.003_bib41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3171\/jns.2002.97.2.0293","article-title":"Surgical complications associated with the endoscopic endonasal transsphenoidal approach for pituitary adenomas","volume":"97","author":"Cappabianca","year":"2002","journal-title":"Journal of Neurosurgery"},{"key":"10.1016\/j.beem.2009.05.003_bib42","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3171\/jns.2003.98.2.0350","article-title":"Endonasal transsphenoidal approach for pituitary adenomas and other sellar lesions: an assessment of efficacy, safety, and patient impressions","volume":"98","author":"Zada","year":"2003","journal-title":"Journal of Neurosurgery"},{"key":"10.1016\/j.beem.2009.05.003_bib43","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0090-3019(02)00892-3","article-title":"Comparison of endonasal endoscopic surgery and sublabial microsurgery for prolactinomas","volume":"58","author":"Cho","year":"2002","journal-title":"Surgical Neurology"},{"key":"10.1016\/j.beem.2009.05.003_bib44","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1179\/016164102101199882","article-title":"Minimally invasive endoscope-assisted endonasal trans-sphenoidal microsurgery for pituitary tumors: experience with 215 cases comparing with sublabial trans-sphenoidal approach","volume":"24","author":"Kawamata","year":"2002","journal-title":"Neurological Research"},{"key":"10.1016\/j.beem.2009.05.003_bib45","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000180098","article-title":"Surgical treatment of prolactinomas. Short- and long-term results, prognostic factors","volume":"22","author":"Charpentier","year":"1985","journal-title":"Hormone Research"},{"key":"10.1016\/j.beem.2009.05.003_bib46","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF01815444","article-title":"Present status of neurosurgery in the treatment of prolactinomas","volume":"8","author":"Fahlbusch","year":"1985","journal-title":"Neurosurgical Review"},{"key":"10.1016\/j.beem.2009.05.003_bib47","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0015-0282(16)45552-4","article-title":"Surgical treatment of pituitary prolactinomas: postoperative prolactin and fertility in seventy patients","volume":"35","author":"Landolt","year":"1981","journal-title":"Fertility and Sterility"},{"key":"10.1016\/j.beem.2009.05.003_bib48","first-page":"161","article-title":"Prolactinomas: surgical therapy, indications and results","volume":"14","author":"Rawe","year":"1980","journal-title":"Surgical Neurology"},{"key":"10.1016\/j.beem.2009.05.003_bib49","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1136\/bmj.291.6508.1547","article-title":"Management of selected patients with hyperprolactinaemia by partial hypophysectomy","volume":"291","author":"Scanlon","year":"1985","journal-title":"British Medical Journal (Clinical Research Ed)"},{"key":"10.1016\/j.beem.2009.05.003_bib50","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1056\/NEJM198308043090505","article-title":"Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma","volume":"309","author":"Serri","year":"1983","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beem.2009.05.003_bib51","series-title":"Pituitary microadenomas","first-page":"483","article-title":"One hundredand ten prolactin secreting adenomas: results of surgical treatment","author":"Nicola","year":"1980"},{"key":"10.1016\/j.beem.2009.05.003_bib52","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3171\/jns.1982.56.1.0033","article-title":"Transsphenoidal microsurgery for prolactin-secreting pituitary adenomas","volume":"56","author":"Faria","year":"1982","journal-title":"Journal of Neurosurgery"},{"key":"10.1016\/j.beem.2009.05.003_bib53","first-page":"108","article-title":"Transsphenoidal microsurgical treatment of prolactin-producing pituitary adenomas. Results in 100 patients","volume":"58","author":"Randall","year":"1983","journal-title":"Mayo Clinic Proceedings Mayo Clinic"},{"key":"10.1016\/j.beem.2009.05.003_bib54","series-title":"Secretory tumors of the pituitary gland","first-page":"73","article-title":"Transsphenoidal microsurgery of prolactinomas","author":"Hardy","year":"1984"},{"key":"10.1016\/j.beem.2009.05.003_bib55","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0026-0495(86)90052-1","article-title":"Gradual recovery of lactotroph responsiveness to dynamic stimulation following surgical removal of prolactinomas: long-term follow-up studies","volume":"35","author":"Arafah","year":"1986","journal-title":"Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib56","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF01456107","article-title":"Results of surgical management of 319 pituitary adenomas","volume":"85","author":"Guidetti","year":"1987","journal-title":"Acta Neurochirurgica"},{"issue":"Suppl.","key":"10.1016\/j.beem.2009.05.003_bib57","first-page":"11","article-title":"Surgical results in microadenomas","volume":"65","author":"Giovanelli","year":"1996","journal-title":"Acta Neurochirurgica"},{"key":"10.1016\/j.beem.2009.05.003_bib58","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00006123-199902000-00006","article-title":"Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results","volume":"44","author":"Tyrrell","year":"1999","journal-title":"Neurosurgery"},{"key":"10.1016\/j.beem.2009.05.003_bib59","first-page":"128","article-title":"The neurosurgical management of prolactinomas","volume":"44","author":"Gokalp","year":"2000","journal-title":"Journal of Neurosurgical Sciences"},{"key":"10.1016\/j.beem.2009.05.003_bib60","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3171\/jns.2002.97.2.0307","article-title":"Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery","volume":"97","author":"Amar","year":"2002","journal-title":"Journal of Neurosurgery"},{"key":"10.1016\/j.beem.2009.05.003_bib61","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1227\/01.NEU.0000159647.64275.9D","article-title":"Results of transsphenoidal surgery in a large series of patients with pituitary adenoma","volume":"56","author":"Mortini","year":"2005","journal-title":"Neurosurgery"},{"key":"10.1016\/j.beem.2009.05.003_bib62","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1365-2265.1990.tb00901.x","article-title":"Long-term follow-up of \u2018cured\u2019 prolactinoma patients after successful adenomectomy","volume":"32","author":"Ciccarelli","year":"1990","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib63","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0090-3019(95)00430-0","article-title":"Transsphenoidal adenomectomy for microprolactinomas: 10 to 20 years of follow-up","volume":"45","author":"Massoud","year":"1996","journal-title":"Surgical Neurology"},{"key":"10.1016\/j.beem.2009.05.003_bib64","first-page":"36","article-title":"Relapse of hyperprolactinemia after transsphenoidal surgery for microprolactinoma: lessons from long-term follow-up","volume":"50","author":"Thomson","year":"2002","journal-title":"Neurosurgery"},{"issue":"Suppl. 3","key":"10.1016\/j.beem.2009.05.003_bib65","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3171\/jns.2000.93.supplement_3.0010","article-title":"Gamma knife radiosurgery as a primary treatment for prolactinomas","volume":"93","author":"Pan","year":"2000","journal-title":"Journal of Neurosurgery"},{"issue":"Suppl. 3","key":"10.1016\/j.beem.2009.05.003_bib66","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3171\/jns.2000.93.supplement_3.0014","article-title":"Gamma knife radiosurgery for prolactinomas","volume":"93","author":"Landolt","year":"2000","journal-title":"Journal of Neurosurgery"},{"issue":"Suppl.","key":"10.1016\/j.beem.2009.05.003_bib67","first-page":"109","article-title":"Stereotactic radiosurgery: the Lyon experience","volume":"63","author":"Rocher","year":"1995","journal-title":"Acta Neurochirurgica"},{"key":"10.1016\/j.beem.2009.05.003_bib68","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3171\/jns.1998.88.1.0043","article-title":"Dose-response tolerance of the visual pathways and cranial nerves of the cavernous sinus to stereotactic radiosurgery","volume":"88","author":"Leber","year":"1998","journal-title":"Journal of Neurosurgery"},{"key":"10.1016\/j.beem.2009.05.003_bib69","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0360-3016(93)90230-S","article-title":"Tolerance of cranial nerves of the cavernous sinus to radiosurgery","volume":"27","author":"Tishler","year":"1993","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.beem.2009.05.003_bib70","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2265.2004.02138.x","article-title":"Radiosurgery for pituitary adenomas","volume":"61","author":"Brada","year":"2004","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib71","first-page":"1022","article-title":"Radiosurgical management of benign cavernous sinus tumors: dose profiles and acute complications","volume":"48","author":"Chen","year":"2001","journal-title":"Neurosurgery"},{"key":"10.1016\/j.beem.2009.05.003_bib72","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0002-9343(86)90299-8","article-title":"Hypopituitarism following radiation therapy of pituitary adenomas","volume":"81","author":"Snyder","year":"1986","journal-title":"The American Journal of Medicine"},{"key":"10.1016\/j.beem.2009.05.003_bib73","first-page":"145","article-title":"Hypopituitarism following external radiotherapy for pituitary tumours in adults","volume":"70","author":"Littley","year":"1989","journal-title":"The Quarterly Journal of Medicine"},{"key":"10.1016\/j.beem.2009.05.003_bib74","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0140-6736(00)04006-X","article-title":"Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group","volume":"357","author":"Tomlinson","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2009.05.003_bib75","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1046\/j.1365-2265.2001.01385.x","article-title":"Is there an increase in second brain tumours after surgery and irradiation for a pituitary tumour?","volume":"55","author":"Erfurth","year":"2001","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib76","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1210\/jc.2004-1152","article-title":"Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years","volume":"90","author":"Minniti","year":"2005","journal-title":"The Journal of Clinical Endocrinology Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib77","first-page":"284","article-title":"Adrenocorticotropic hormone-producing pituitary tumors: 12- to 22-year follow-up after treatment with stereotactic radiosurgery","volume":"49","author":"Hoybye","year":"2001","journal-title":"Neurosurgery"},{"key":"10.1016\/j.beem.2009.05.003_bib78","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.3171\/foc.2003.14.5.11","article-title":"Stereotactic radiosurgery for pituitary tumors","volume":"14","author":"Witt","year":"2003","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.beem.2009.05.003_bib79","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3171\/jns.2005.102.4.0678","article-title":"Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium","volume":"102","author":"Sheehan","year":"2005","journal-title":"Journal of Neurosurgery"},{"key":"10.1016\/j.beem.2009.05.003_bib80","first-page":"452","article-title":"Treatment of prolactinomas","volume":"30","author":"Colao","year":"1998","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.beem.2009.05.003_bib81","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1517\/13543784.11.6.787","article-title":"Dopamine receptor agonists for treating prolactinomas","volume":"11","author":"Colao","year":"2002","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.beem.2009.05.003_bib82","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJM198608283150903","article-title":"Increase in bone mass after treatment of hyperprolactinemic amenorrhea","volume":"315","author":"Klibanski","year":"1986","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beem.2009.05.003_bib83","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1210\/jcem.83.3.4674","article-title":"Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males","volume":"83","author":"Di Somma","year":"1998","journal-title":"The Journal of Clinical Endocrinology Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib84","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1530\/eje.0.1380286","article-title":"Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine","volume":"138","author":"De Rosa","year":"1998","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib85","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","article-title":"Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy","volume":"86","author":"Di Sarno","year":"2001","journal-title":"The Journal of Clinical Endocrinology Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib86","article-title":"Medical therapy of pituitary adenomas: effects on tumor shrinkage","author":"Colao","year":"2008","journal-title":"Reviews in Endocrine & Metabolic Disorders"},{"key":"10.1016\/j.beem.2009.05.003_bib87","first-page":"2247","article-title":"Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients","volume":"85","author":"Colao","year":"2000","journal-title":"The Journal of Clinical Endocrinology Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib88","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1210\/jcem-72-3-635","article-title":"A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia","volume":"72","author":"Lamberts","year":"1991","journal-title":"The Journal of Clinical Endocrinology Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib89","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1530\/eje.0.1350548","article-title":"Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males","volume":"135","author":"Colao","year":"1996","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib90","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1056\/NEJM198509123131103","article-title":"Low doses of dopamine agonists in the long-term treatment of macroprolactinomas","volume":"313","author":"Liuzzi","year":"1985","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beem.2009.05.003_bib91","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1210\/jcem-63-4-1002","article-title":"Chronic treatment of pathological hyperprolactinemia and acromegaly with the new ergot derivative terguride","volume":"63","author":"Dallabonzana","year":"1986","journal-title":"The Journal of Clinical Endocrinology Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib92","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/bmj.289.6452.1101","article-title":"Psychotic reactions during treatment of pituitary tumours with dopamine agonists","volume":"289","author":"Turner","year":"1984","journal-title":"British Medical Journal (Clinical Research Ed)"},{"key":"10.1016\/j.beem.2009.05.003_bib93","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"The\u00a0New England Journal of Medicine"},{"key":"10.1016\/j.beem.2009.05.003_bib94","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation","volume":"356","author":"Schade","year":"2007","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beem.2009.05.003_bib95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-08-0213","article-title":"Cabergoline and the risk of valvular lesions in endocrine disease","volume":"159","author":"Lancellotti","year":"2008","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib96","article-title":"Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas","author":"Vallette","year":"2008","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2009.05.003_bib97","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1210\/jc.2007-2658","article-title":"Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma","volume":"93","author":"Kars","year":"2008","journal-title":"The Journal of Clinical Endocrinology Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib98","doi-asserted-by":"crossref","first-page":"672","DOI":"10.4158\/EP.14.6.672","article-title":"Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia","volume":"14","author":"Devin","year":"2008","journal-title":"Endocrine Practice"},{"key":"10.1016\/j.beem.2009.05.003_bib99","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1210\/jc.2007-1403","article-title":"Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline","volume":"93","author":"Colao","year":"2008","journal-title":"The Journal of Clinical Endocrinology Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib100","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1530\/EJE-08-0365","article-title":"Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease","volume":"159","author":"Wakil","year":"2008","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib101","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/j.1742-1241.2008.01779.x","article-title":"Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia","volume":"62","author":"Bogazzi","year":"2008","journal-title":"International Journal of Clinical Practice"},{"key":"10.1016\/j.beem.2009.05.003_bib102","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2265.2008.03458.x","article-title":"Valvular heart disease and the use of cabergoline for the treatment of prolactinoma","volume":"70","author":"Herring","year":"2009","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib103","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1210\/jc.2007-2758","article-title":"Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients","volume":"93","author":"Ono","year":"2008","journal-title":"The Journal of Clinical Endocrinology Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib104","unstructured":"Nachtigall LB, Valassi E, McCaty D, et\u00a0al. Cardiac valvular function in hyperprolactinemic patients receiving cabergoline. Program of the 90th Annual Meeting of The Endocrine Society, San Francisco, CA, 2008, p 124 [Abstract OR27-2]."},{"key":"10.1016\/j.beem.2009.05.003_bib105","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-08-0611","article-title":"Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required","volume":"159","author":"Kars","year":"2008","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib106","first-page":"868","article-title":"Hyperprolactinemia. Long-term effects of bromocriptine","volume":"75","author":"Johnston","year":"1983","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.beem.2009.05.003_bib107","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa022657","article-title":"Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia","volume":"349","author":"Colao","year":"2003","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beem.2009.05.003_bib108","first-page":"139","article-title":"Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine","volume":"104","author":"Zarate","year":"1983","journal-title":"Acta Endocrinologica"},{"key":"10.1016\/j.beem.2009.05.003_bib109","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(84)90480-X","article-title":"Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography","volume":"2","author":"Johnston","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2009.05.003_bib110","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0015-0282(16)47593-X","article-title":"Hyperprolactinemic response after bromocriptine withdrawal in women with prolactin-secreting pituitary tumors","volume":"41","author":"Maxson","year":"1984","journal-title":"Fertility and Sterility"},{"key":"10.1016\/j.beem.2009.05.003_bib111","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1210\/jcem-60-4-764","article-title":"Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal","volume":"60","author":"Moriondo","year":"1985","journal-title":"The Journal of Clinical Endocrinology Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib112","series-title":"Basic and clinical correlates","first-page":"817","article-title":"Persisting normoprolactinemia after withdrawal of bromocriptine long-term therapy in patients with prolactinomas","author":"Winkelmann","year":"1985"},{"key":"10.1016\/j.beem.2009.05.003_bib113","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2265.1987.tb01163.x","article-title":"Long-term treatment of hyperprolactinaemia with bromocriptine: effect of drug withdrawal","volume":"27","author":"Wang","year":"1987","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib114","first-page":"170","article-title":"Clinical response and prolactin concentration in hyperprolactinemic women during and after treatment for 24 months with the new dopamine agonist, CV 205-502","volume":"125","author":"Rasmussen","year":"1991","journal-title":"Acta Endocrinologica"},{"key":"10.1016\/j.beem.2009.05.003_bib115","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2265.1991.tb00289.x","article-title":"Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size","volume":"34","author":"van't Verlaat","year":"1991","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib116","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1210\/jcem.87.8.8722","article-title":"Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal","volume":"87","author":"Passos","year":"2002","journal-title":"The Journal of Clinical Endocrinology Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib117","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1365-2265.2005.02293.x","article-title":"Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas","volume":"63","author":"Biswas","year":"2005","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib118","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2265.2000.01016.x","article-title":"The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas","volume":"53","author":"Di Sarno","year":"2000","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib119","first-page":"489","article-title":"Cabergoline in the long-term therapy of hyperprolactinemic disorders","volume":"126","author":"Ferrari","year":"1992","journal-title":"Acta Endocrinologica"},{"key":"10.1016\/j.beem.2009.05.003_bib120","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/BF03348016","article-title":"Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients","volume":"20","author":"Muratori","year":"1997","journal-title":"Journal of Endocrinological Investigation"},{"key":"10.1016\/j.beem.2009.05.003_bib121","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF03343573","article-title":"Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma","volume":"22","author":"Cannav\u00f2","year":"1999","journal-title":"Journal of Endocrinological Investigation"},{"key":"10.1016\/j.beem.2009.05.003_bib122","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2265.2007.02905.x","article-title":"Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy","volume":"67","author":"Colao","year":"2007","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib123","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0028-2243(92)90094-F","article-title":"Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women","volume":"44","author":"Crosignani","year":"1992","journal-title":"European Journal of Obstetrics, Gynecology, and Reproductive Biology"},{"key":"10.1016\/j.beem.2009.05.003_bib124","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2265.1996.00824.x","article-title":"Long-term follow-up of patients with hyperprolactinaemia","volume":"45","author":"Jeffcoate","year":"1996","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib125","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1365-2265.2001.01190.x","article-title":"The effect of the menopause on prolactin levels in patients with hyperprolactinaemia","volume":"54","author":"Karunakaran","year":"2001","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib126","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1210\/jc.2008-2244","article-title":"The cabergoline-resistant prolactinoma patient: new challenges","volume":"93","author":"Molitch","year":"2008","journal-title":"The Journal of Clinical Endocrinology Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib127","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1210\/jcem-51-5-1037","article-title":"Dopaminergic receptors in human prolactin-secreting adenomas: a quantitative study","volume":"51","author":"Bression","year":"1980","journal-title":"The Journal of Clinical Endocrinology Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib128","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1210\/jcem-69-3-500","article-title":"Resistance to bromocriptine in prolactinomas","volume":"69","author":"Pellegrini","year":"1989","journal-title":"The Journal of Clinical Endocrinology Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib129","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000126764","article-title":"Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas","volume":"60","author":"Caccavelli","year":"1994","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib130","first-page":"568","article-title":"Normal structural dopamine type 2 receptor gene in prolactin-secreting and other pituitary tumors","volume":"78","author":"Friedman","year":"1994","journal-title":"The Journal of Clinical Endocrinology Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib131","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/tpj.2008.1","article-title":"Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas","volume":"8","author":"Filopanti","year":"2008","journal-title":"The Pharmacogenomics Journal"},{"key":"10.1016\/j.beem.2009.05.003_bib132","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF03350560","article-title":"Reenlargement of macroprolactinomas during bromocriptine treatment: report of two cases","volume":"6","author":"Dallabonzana","year":"1983","journal-title":"Journal of Endocrinological Investigation"},{"key":"10.1016\/j.beem.2009.05.003_bib133","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/bmj.287.6390.451","article-title":"Failure of bromocriptine to maintain reduction in size of a macroprolactinoma","volume":"287","author":"Breidahl","year":"1983","journal-title":"British Medical Journal (Clinical Research Ed)"},{"key":"10.1016\/j.beem.2009.05.003_bib134","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1530\/eje.0.1460081","article-title":"Retention of dopamine 2 receptor mRNA and absence of the protein in craniospinal and extracranial metastasis of a malignant prolactinoma: a case report","volume":"146","author":"Winkelmann","year":"2002","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib135","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000023180","article-title":"Late development of resistance to bromocriptine in a patient with macroprolactinoma","volume":"49","author":"Delgrange","year":"1998","journal-title":"Hormone Research"},{"key":"10.1016\/j.beem.2009.05.003_bib136","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","article-title":"Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients","volume":"84","author":"Verhelst","year":"1999","journal-title":"The Journal of Clinical Endocrinology Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib137","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1210\/jcem.82.3.3822","article-title":"Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment","volume":"82","author":"Colao","year":"1997","journal-title":"The Journal of Clinical Endocrinology Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib138","first-page":"577","article-title":"Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine","volume":"74","author":"Brue","year":"1992","journal-title":"The Journal of Clinical Endocrinology Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib139","first-page":"449","article-title":"Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502","volume":"39","author":"Glaser","year":"1994","journal-title":"The Journal of Reproductive Medicine"},{"key":"10.1016\/j.beem.2009.05.003_bib140","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1530\/eje.0.1350413","article-title":"Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy","volume":"135","author":"Morange","year":"1996","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib141","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/BF03343751","article-title":"A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients","volume":"23","author":"De Luis","year":"2000","journal-title":"Journal of Endocrinological Investigation"},{"key":"10.1016\/j.beem.2009.05.003_bib142","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1365-2265.2000.01147.x","article-title":"Cabergoline and quinagolide therapy for prolactinomas","volume":"53","author":"Webster","year":"2000","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib143","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2265.1986.tb01647.x","article-title":"Discordant responses of prolactinoma to two different dopamine agonists","volume":"24","author":"Ahmed","year":"1986","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib144","first-page":"375","article-title":"Long-term pergolide treatment of hyperprolactinemic patients previously unsuccessfully treated with dopaminergic drugs","volume":"27","author":"Berezin","year":"1991","journal-title":"Israel Journal of Medical Sciences"},{"key":"10.1016\/j.beem.2009.05.003_bib145","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1210\/jcem-60-4-698","article-title":"Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study","volume":"60","author":"Molitch","year":"1985","journal-title":"The Journal of Clinical Endocrinology Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib146","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1210\/jcem.85.1.6329","article-title":"Long-term treatment of prolactin-secreting macroadenomas with pergolide","volume":"85","author":"Freda","year":"2000","journal-title":"The\u00a0Journal of Clinical Endocrinology Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib147","unstructured":"Colao A, Ochoa AS, Auriemma RS, et\u00a0al. Pituitary carcinomas. Frontiers of Hormone Research, in press."},{"key":"10.1016\/j.beem.2009.05.003_bib148","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0015-0282(16)44178-6","article-title":"Induction of ovulation in women with hyperprolactinemic amenorrhea using clomiphene and human chorionic gonadotropin of bromocriptine","volume":"32","author":"Radwanska","year":"1979","journal-title":"Fertility and Sterility"},{"key":"10.1016\/j.beem.2009.05.003_bib149","first-page":"440","article-title":"Pulsatile GnRH therapy\u2013an alternative successful therapy for induction of ovulation in infertile normo- and hyperprolactinaemic amenorrhoeic women with pituitary tumours","volume":"110","author":"Bergh","year":"1985","journal-title":"Acta Endocrinologica"},{"key":"10.1016\/j.beem.2009.05.003_bib150","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S0015-0282(16)49899-7","article-title":"Treatment of hyperprolactinemic amenorrhea with pulsatile gonadotropin-releasing hormone therapy","volume":"46","author":"Gindoff","year":"1986","journal-title":"Fertility and Sterility"},{"key":"10.1016\/j.beem.2009.05.003_bib151","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1471-0528.1978.tb14949.x","article-title":"Induction of ovulation with clomiphene and human chorionic gonadotrophin in women with hyperprolactinaemic amenorrhoea","volume":"85","author":"McGarrigle","year":"1978","journal-title":"British Journal of Obstetrics and Gynaecology"},{"key":"10.1016\/j.beem.2009.05.003_bib152","first-page":"1507","article-title":"Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. The European Recombinant Human LH Study Group","volume":"83","year":"1998","journal-title":"The Journal of Clinical Endocrinology Metabolism"},{"key":"10.1016\/j.beem.2009.05.003_bib153","first-page":"425","article-title":"Prolactin-producing microadenomas in pregnancy","volume":"62","author":"Divers","year":"1983","journal-title":"Obstetrics and Gynecology"},{"issue":"1","key":"10.1016\/j.beem.2009.05.003_bib154","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2265.2007.03000.x","article-title":"Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study","volume":"8","author":"Colao","year":"2008","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib155","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2265.1986.tb01698.x","article-title":"Failure of prophylactic surgery to avert massive pituitary expansion in pregnancy","volume":"25","author":"Belchetz","year":"1986","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.beem.2009.05.003_bib156","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0015-0282(16)47888-X","article-title":"Pregnancy in hyperprolactinemic women","volume":"41","author":"Ruiz-Velasco","year":"1984","journal-title":"Fertility and Sterility"},{"issue":"1","key":"10.1016\/j.beem.2009.05.003_bib157","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ecl.2005.09.011","article-title":"Pituitary disorders during pregnancy","volume":"35","author":"Molitch","year":"2006","journal-title":"Endocrinology and Metabolism Clinics of North America"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X09000475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X09000475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:42:57Z","timestamp":1761496977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X09000475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":157,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S1521690X09000475"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2009.05.003","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prolactinoma","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2009.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}